Protagonist and Takeda Bring Phase 3 VERIFY and Long-Term Rusfertide Data to EHA 2026 in Stockholm Through June 14
Protagonist Therapeutics (Nasdaq: PTGX) and Takeda are presenting four rusfertide abstracts at the 2026 European Hematology Association Congress in Stockholm (June 11-14), including analyses from the Phase 3 VERIFY study and long-term results from the Phase 2 REVIVE and THRIVE open-label extensions. The 32-week VERIFY primary analysis showed 76.9% of patients on rusfertide achieved a clinical response versus 32.9% on placebo; the 52-week dataset met the primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class subcutaneous hepcidin-mimetic peptide for polycythemia vera. The FDA accepted the rusfertide NDA in early 2026 with priority review and set a Q3 2026 PDUFA target action date.